We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+11.94%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$1.73B
AUM Growth
+$6.46M
Cap. Flow
-$42.8M
Cap. Flow %
-2.48%
Top 10 Hldgs %
30.81%
Holding
279
New
77
Increased
40
Reduced
47
Closed
83

Top Buys

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$14.4M
2
ILMN icon
Illumina
ILMN
+$11.2M
3
ICUI icon
ICU Medical
ICUI
+$10.4M
4
OLK
Olink Holding AB (publ) American Depositary Shares
OLK
+$9.5M
5
OM icon
Outset Medical
OM
+$8.23M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$20.5M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$13.9M
3
LUNG icon
Pulmonx
LUNG
+$10.1M
4
NSTG
NanoString Technologies, Inc.
NSTG
+$9.8M
5
EVH icon
Evolent Health
EVH
+$7.06M

Sector Composition

Rank Sector Weight
1 Healthcare 34.81%
2 Industrials 0.32%
3 Materials 0.15%
4 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVTX icon
251
Travere Therapeutics
TVTX
$5.86B
– –
-166,201
Closed -$4.03M
UBX
252
CALL
DELISTED
Unity Biotechnology
UBX
– –
-78,380
Closed -$442K
UBX
253
DELISTED
Unity Biotechnology
UBX
– –
-35,909
Closed -$202K
UPC icon
254
Universe Pharmaceuticals Inc
UPC
$3.93M
– –
-67
Closed -$150K
XENE icon
255
Xenon Pharmaceuticals
XENE
$6.31B
– –
-40,002
Closed -$1.22M
ZBH icon
256
PUT
Zimmer Biomet
ZBH
$18.7B
– –
-50,000
Closed -$5.25M
ZYME icon
257
Zymeworks
ZYME
$1.77B
– –
-44,696
Closed -$237K
CMRX
258
DELISTED
Chimerix, Inc.
CMRX
– –
-384,905
Closed -$801K
SNAX
259
DELISTED
Stryve Foods, Inc. Class A Common Stock
SNAX
– –
-53,333
Closed -$705K
VINC
260
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
– –
-5,423
Closed -$143K
CERE
261
CALL
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
– –
-243,400
Closed -$6.43M
OLK
262
CALL
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
– –
-590,000
Closed -$8.97M
KRTX
263
CALL
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-3,100
Closed -$392K
KRTX
264
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-29,900
Closed -$3.78M
KRTX
265
PUT
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-25,500
Closed -$3.23M
SLGC
266
CALL
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
– –
-605,500
Closed -$2.74M
AMRS
267
CALL
DELISTED
Amyris Inc.
AMRS
– –
-1,761,000
Closed -$3.26M
BLU
268
DELISTED
BELLUS Health Inc.
BLU
– –
-122,000
Closed -$1.13M
CNCE
269
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-44,357
Closed -$187K
LHDX
270
DELISTED
Lucira Health, Inc. Common Stock
LHDX
– –
-690,663
Closed -$1.28M
MTCR
271
DELISTED
Metacrine, Inc. Common Stock
MTCR
– –
-198,230
Closed -$99K
TCDA
272
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-49,900
Closed -$546K
ABMD
273
PUT
DELISTED
Abiomed Inc
ABMD
– –
-25,000
Closed -$6.19M
CLVS
274
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-284,000
Closed -$511K
GBT
275
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-14,454
Closed -$462K
8 9 10
11
12

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q3 2022 Portfolio in Review

As of Q3 2022, Pura Vida Investments held 279 positions worth $1.73B, up 0.38% from $1.72B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Pura Vida Investments's Q3 2022 filing shows 77 new, 40 increased, 47 reduced and 83 closed positions. Its largest new stake was Illumina: 56,540 shares worth $10.5M. The largest sale was Biogen, an estimated $20.5M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 33% a quarter earlier, followed by Industrials and Materials.

  • Pura Vida Investments's largest Q3 2022 buy was Illumina: 56,540 shares worth $10.5M.
  • Pura Vida Investments added most to United Therapeutics in Q3 2022, an estimated $14.4M increase.
  • Pura Vida Investments's biggest Q3 2022 reduction was Biogen, cutting an estimated $20.5M.
  • Pura Vida Investments fully exited Alnylam Pharmaceuticals in Q3 2022, selling an estimated $13.9M.
  • Pura Vida Investments's ten largest holdings make up 31% of its $1.73B portfolio in Q3 2022.
  • Pura Vida Investments opened 77 new positions and closed 83 in Q3 2022.
  • Pura Vida Investments's portfolio value rose 0.38% quarter-over-quarter to $1.73B.

Based on Pura Vida Investments's 13F filing for Q3 2022, filed 14 Nov 2022.